Collegium Pharmaceutical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-7.8%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$836.8Mnext fiscal year
Monitoring Framework
Key Performance Indicators
JORNAY PM Net Product Revenue Quarterly38.9MTarget: 190000000 to 200000000
Total Net Product Revenues Quarterly193.5MTarget: 805000000 to 825000000
Adjusted EBITDA Quarterly103.9MTarget: 455000000 to 475000000
Watch Items
- Integration and closing of the AZSTARYS acquisitionTrigger: Expected close in Q2 2026Action: Monitor regulatory approvals, final transaction close, and subsequent updates to the full-year 2026 corporate guidance.
- Generic erosion of the pain portfolioTrigger: Launch of authorized generic versions of Nucynta and Nucynta ER in early 2026Action: Track the net profit share received from Hikma Pharmaceuticals USA Inc. to evaluate the offset of branded revenue declines.
Research as of 20 Jun 2026